7 March 2012 - Molecular information company Foundation Medicine Inc on Tuesday announced that it is collaborating with Array BioPharma (NASDAq:ARRY).

Under the collaboration Foundation Medicine will use its genomic sequencing and analytical capabilities to assess potentially relevant molecular alterations which will be used to assist Array in targeting patients who are most likely to respond to treatment.

Through this collaboration Array intends to determine the genetic profile of tumours of patients who are treated with certain of its anticancer agents. The aim of this work is to understand how to identify patients who may respond to a given targeted therapy to ensure that each patient gets the optimal drug to treat their individual disease.